Matthew J. Lazzara

About

Matthew J. Lazzara, PhD, is a Professor of Chemical Engineering and Biomedical Engineering at the University of Virginia. He is also a member of the UVA Cancer Center. Dr. Lazzara earned his Bachelor of Science degree from the University of Florida in 1997 and completed his Ph.D. at the Massachusetts Institute of Technology in 2003. Following his doctoral studies, he conducted postdoctoral research at MIT from 2003 to 2007. His academic appointments and affiliations reflect a strong interdisciplinary focus bridging chemical engineering, biomedical engineering, and cancer research.

Research topics

• Biology
• Cancer research
• Cell biology
• Biochemistry
• Internal medicine
• Medicine
• Genetics
• Immunology
• Chemistry

Selected publications

• Calcium-stimulated disassembly of focal adhesions mediated by an ORP3/IQSec1 complex

  eLife · 2020 · 80 citations

  influx triggers PKC-dependent translocation of this complex to ER/plasma membrane (PM) contact sites adjacent to FAs. In addition to allosterically activating IQSec1, ORP3 also extracts PI4P from the PM, in exchange for phosphatidylcholine. ORP3-mediated lipid exchange is also important for FA turnover. Together, these findings identify a new pathway that links calcium influx to FA turnover during cell migration.

  DOI

• Glioblastoma Cell Resistance to EGFR and MET Inhibition Can Be Overcome via Blockade of FGFR-SPRY2 Bypass Signaling

  Cell Reports · 2020 · 39 citations

  Senior authorCorresponding

  SPRY2 is a purported tumor suppressor in certain cancers that promotes tumor growth and resistance to receptor tyrosine kinase inhibitors in glioblastoma. Here, we identify a SPRY2-dependent bypass signaling mechanism in glioblastoma that drives resistance to EGFR and MET inhibition. In glioblastoma cells treated with EGFR and MET inhibitors, SPRY2 expression is initially suppressed but eventually rebounds due to NF-κB pathway activation, resultant autocrine FGFR activation, and reactivation of…

  DOI

• CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Activation in Ovarian Cancer

  Cancers · 2021 · 26 citations

  Epithelial ovarian cancer (EOC) is the deadliest of the gynecologic malignancies, with an overall survival rate of <30%. Recent research has suggested that targeting RNA polymerase I (POL I) with small-molecule inhibitors may be a viable therapeutic approach to combating EOC, even when chemoresistance is present. CX-5461 is one of the most promising POL I inhibitors currently being investigated, and previous reports have shown that CX-5461 treatment induces DNA damage response (DDR) through ATM/…

  DOI

• Systems Biology of the Cancer Cell

  Annual Review of Biomedical Engineering · 2024-12-17 · 9 citations

  reviewOpen accessSenior author

  Questions in cancer have engaged systems biologists for decades. During that time, the quantity of molecular data has exploded, but the need for abstractions, formal models, and simplifying insights has remained the same. This review brings together classic breakthroughs and recent findings in the field of cancer systems biology, focusing on cancer cell pathways for tumorigenesis and therapeutic response. Cancer cells mutate and transduce information from their environment to alter gene expressi…

  PublisherDOI

• Breast Cancer Antiestrogen Resistance 3 (BCAR3) promotes tumor growth and progression in triple-negative breast cancer.

  2021 · 8 citations

  (DCIS) and invasive carcinomas compared to normal mammary tissue, and that survival of TNBC patients whose tumors contained elevated BCAR3 mRNA is reduced relative to individuals whose tumors had less BCAR3 mRNA. Using mouse orthotopic tumor models, we further show that BCAR3 is required for efficient TNBC tumor growth. Analysis of publicly available RNA expression databases revealed that MET receptor signaling is strongly correlated with BCAR3 mRNA expression. A functional role for BCAR3-MET co…

Recent grants

• Engineering Proteins for Reabsorption in the Renal Proximal Tubule

  NSF · $94k · 2016–2019

• UNS: Developing Quantitative Models of SHP2-Mediated Signaling regulation in Glioma for Rational Identification of Improved Therapeutic Approaches.

  NSF · $325k · 2015–2017

• EAGER: Spatiotemporal Regulation of Receptor-Initiated Intracellular Complexes of Signaling Proteins

  NSF · $100k · 2014–2016

Frequent coauthors

• Calixte S. Monast

  45 shared

• M. Celeste Simon

  44 shared

• Madhavi Tadi

  42 shared

• Paul J. Myers

  42 shared

• Lynette M. Sholl

  Brigham and Women's Hospital

  42 shared

• Christine A. Pratilas

  Johns Hopkins University

  42 shared

• Takeshi Shimamura

  University of Illinois Chicago

  42 shared

• Mohit Butaney

  Henry Ford Health System

  42 shared

Labs

• Lazzara LabPI

Awards & honors

• S. Reid Warren, Jr. Award
• Outstanding Faculty Award of the AIChE Delaware Valley
• NIH Ruth L. Kirschstein National Research Service Award Post…

Similar researchers at University of Virginia

• Jennifer L. Westh-93
• Bryan Bergerh-26
• Steven R. Caliarih-26